Conclusion: Sorafenib inhibits proliferation and migration but not invasion in colorectal cancer. Combination therapies with 5-FU, oxaliplatin or irinotecan deem not feasible.

181 POSTER

Inhibition of erlotinib on bone metastasis of human non-small-cell lung cancer cell line NCI-H292

K. Furugaki[1], Y. Moriya[1], T. Iwai[1], M. Yanagisawa[1], K. Yorozu[1], K. Fujimoto-Ouchi[1]. [1]*Chugai Pharmaceutical Co. Ltd., Product Research Department, Kamakura Kanagawa, Japan*

Background: Bone metastases occur in 30−40% of non-small-cell lung cancer (NSCLC) patients, and are often associated with significant morbidity. Previous pre-clinical and clinical findings suggested a potential role of epidermal growth factor receptor (EGFR) in osteoclast differentiation and the pathogenesis of bone metastasis. In the present study, we investigated the effect of erlotinib, an orally active EGFR tyrosine kinase inhibitor, on the bone metastases of human non-small-cell lung cancer (NSCLC) cell line NCI-H292.
Material and Methods: To establish a novel bone metastasis model, the NCI-H292 cells were injected into both tibiae and the mice were randomly divided into two groups of 10 mice on day 1. The mice were daily administered either oral erlotinib (75 mg/kg/day) or vehicle (Captisol) for 27 days from day 1. For the in vitro cell proliferation assay, NCI-H292 cells were seeded into 96-well plates. On the following day, cells were treated with erlotinib for 4 days and then MTT assays were done. The concentration of osteolytic factors produced by NCI-H292 cells in the culture media was determined by immunoassays. To investigate the inhibitory effect of erlotinib on the osteoclast differentiation, the standard osteoclast differentiation culture system using mouse bone marrow cells was used.
Results: We established a novel bone metastasis model of NCI-H292 cells. In this model, erlotinib significantly inhibited osteolytic bone destruction of NCI-H292 cells ($P < 0.05$). Erlotinib showed a marked inhibition of NCI-H292 cell proliferation *in vitro*, and the IC_{50} value was 0.08 μM. Furthermore, erlotinib suppressed the production of osteolytic factors, such as parathyroid hormone-related protein (PTHrP), IL-8, IL-11 and vascular endothelial growth factor (VEGF) in NCI-H292 cells. In addition to the effects for NCI-H292 cells, erlotinib also inhibited osteoclast differentiation from mouse bone marrow cells.
Conclusion: Erlotinib inhibits tumor-induced osteolytic metastases by the effect of suppressing tumor growth as well as suppressing osteoclast development, by blocking osteolytic factor production in tumor cells, and osteoclast differentiation from bone marrow.

182 POSTER

Defining efficacy thresholds in preclinical models of cancer: a comparative analysis of cetuximab efficacy and biomarkers in colorectal cancer models

M. Prewett[1], R. Bassi[1], K. Paz[2], M. Amatulli[2], S. Samakoglu[1], J.R. Tonra[1]. [1]*ImClone Systems, Preclinical Pharmacology, New York NY, USA;* [2]*ImClone Systems, Cell Biology, New York NY, USA*

Clinical studies have demonstrated a dramatic difference in clinical benefit with epidermal growth factor receptor (EGFR) antibodies in metastatic colorectal cancer (mCRC) patients with wild type (WT) versus mutant (MT) KRAS gene harboring tumors. These findings provide a unique opportunity to address a frequent issue arising in preclinical cancer drug development, i.e. the criteria for efficacy in cancer models predictive of clinical benefits.
The chimeric antibody to EGFR, cetuximab (Erbitux®), was tested alone or in combination with irinotecan+oxaliplatin [IROX] in 13 subcutaneous xenograft tumor models established in mice with human CRC cell lines. Cetuximab has previously been shown to increase the effects of these chemotherapies. KRAS mutation status was evaluated by sequencing and EGFR gene copy number was evaluated by RT-PCR for each CRC cell line utilized.
With a threshold for efficacy of T/C% (Treatment/Control relative tumor volume ratio) $\leqslant$ 50%, cetuximab alone was efficacious in 50% of KRAS MT models and 57% of KRAS WT models tested. Cetuximab+IROX was efficacious in 100% of KRAS MT models and 71% of KRAS WT models. Utilizing a threshold for efficacy of tumor regression ($\geqslant$25% decrease in tumor volume in $\geqslant$10% of mice), cetuximab alone was efficacious in 8% of KRAS WT models (DiFi model). A very high EGFR gene copy number in DiFi (535 copies) stands out as a potential biomarker for this significant level of activity. Cetuximab + IROX was efficacious in 50% of KRAS MT models and 43% of KRAS WT models, while IROX alone was not efficacious. The benefits of adding IROX to cetuximab were mostly related to the effects of irinotecan, although the percentage of mice achieving tumor regression was generally increased by including oxaliplatin in the combination.
Subcutaneous xenograft models of colorectal cancer do not predict the clinically demonstrated KRAS dependence for the benefits of an EGFR antibody when T/C% $\leqslant$ 50% is utilized to claim the treatment "works". Results may speak against the validity of these models, or may support shifting the threshold for response away from tumor growth inhibition towards partial or complete tumor regressions for advancement of therapeutic strategies into clinical testing. In this regard, significant preclinical benefits of cetuximab in combination with IROX demonstrated in KRAS MT models may indicate the potential for clinically demonstrable benefits of anti-EGFR therapy in novel combination strategies.

183 POSTER

Amino-alkyl substituted fused imidazoles: potent, selective and orally bioavailable inhibitors of PI3K

J. Pastor[1], S. Martínez[1], R.M. Álvarez[1], C. Varela[1], A.I. Hernández[1], S. Rodríguez[1], J. Oyarzábal[1], M. Albarrán[1], W. Link[1], J.R. Bischoff[1]. [1]*Spanish National Cancer Research Centre, Experimental Therapeutics, Madrid, Spain*

The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays a crucial role in cell growth, proliferation and survival. This pathway is activated in a variety of solid and non-solid tumors. In many instances this is due to either activating mutations in the catalytic subunit of PI3Ka, p110α; or inactivating mutations or deletions of the tumor suppressor PTEN.
In addition, persistent signaling through the PI3K/Akt pathway has been shown to be a major mechanism of resistance to therapy. Hence, PI3K, and in particular the p110α subunit of PI3K, is a highly promising candidate for cancer therapy.
Using a rational drug design strategy, we identified a novel fused imidazoles series, with potent activity against PI3Kα Depending on the C-2 substitution fragment we have observed different isoforms profiles. Here, we describe the design, synthesis and biological characterization of C-2 amino alkyl fused imidazoles subseries, reporting its SAR/SPR (ADME).
We identified lead compounds with potency in the low nanomolar range *vs.* p110α and d, selective versus the other isoforms and versus other related PIKK family members such as mTOR, DNA-PK or ATR. In general, this series show high selectivity versus a 24 kinase panel. The compounds display cellular activity by blocking PI3K signaling, S473 P-Akt in U2OS cells, in the low nanomolar range.
Finally, we will show in vivo PK data for selected compounds.

184 POSTER

Histone deacetylase inhibitor Belinostat (PXD-101) represses androgen receptor expression and acts synergistically with castration and bicalutamide treatment to inhibit prostate cancer growth hormone refractory models

C. Festuccia[1], G.L. Gravina[1], F. Marampon[1], L.A. Biordi[1], E. Ricevuto[1], C. Ficorella[1], V. Tombolini[1]. [1]*University of L'Aquila, Experimental Medicine, L'Aquila, Italy*

Background: Growth of prostate cancer cells is initially androgen dependent. However, resistance to hormone therapy inevitably occurs. Histone deacetylase (HDAC) inhibitors are currently undergoing clinical trials in cancer patients on the basis of their effect. One of them is the hydroxamic acid belinostat (PXD101) that has demonstrated therapeutic efficacy for several clinical indications.
Materials and Methods: We investigated the in vitro effects of PXD-101 in a panel of prostate cancer cells and the in vivo effects of this drug using two aggressive hormone refractory prostate cancer cell lines expressing (22rv1) or not (PC3) the AR.
Results: PXD101 rapidly induced histone H3 and H4 acetylation and upregulated p21 expression. PXD101 significantly decreased also the expression of the cell cycle regulatory proteins (p27, cyclin D1/cyclin dependent kinase (CDK) 4, CDK6, and cyclin E/CDK2) with reduced mitotic rate and accumulation of cells both in G0/G1 and in G_2-M cell cycle phase. Apoptosis was associated with up-regulation of the pro-death Bak and Bim, as well as with attenuation of the levels of Akt, XIAP, survivin, Bcl-2, and Bcl-x_L. The effects were higher in less differentiated cells when compared to more differentiated androgen sensitive cells. In mice bearing 22rv1 tumors, PXD101 (20 mg/kg/biday) caused significant suppression of tumor growth compared with mice receiving vehicle alone and treatment with 40 mg/kg/day resulted in a 60% reduction in the mean final tumor volume compared with controls. In PC3 bearing mice, 40 mg/Kg, bid, i.p PXD101 reduced PC3\ tumor proliferation of about 47%. The apoptotic program was triggered both in acute treatment with high PXD101 dose (>1.0 mM) and in chronic treatment (from 10−14 days) with low doses of drug (< 0.1 mM). The significant effects of chronic treatments suggest the possibility to use low doses of this drug to reduce the side effects. Culture of 22rv1 cells in steroid-free medium sensitized these cells to